These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 30572540)

  • 21. Identifying gene modules of thyroid cancer associated with pathological stage by weighted gene co-expression network analysis.
    Tang X; Huang X; Wang D; Yan R; Lu F; Cheng C; Li Y; Xu J
    Gene; 2019 Jul; 704():142-148. PubMed ID: 30965127
    [TBL] [Abstract][Full Text] [Related]  

  • 22. BRAFV600E mutation and X-linked inhibitor of apoptosis expression in papillary thyroid carcinoma.
    Gu LQ; Li FY; Zhao L; Liu Y; Zang XX; Wang TX; Chen HP; Ning G; Zhao YJ
    Thyroid; 2009 Apr; 19(4):347-54. PubMed ID: 19355825
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differential expression of a set of microRNA genes reveals the potential mechanism of papillary thyroid carcinoma.
    Feng Z; Song Y; Qian J; Chen T; Yang C; Jia L; Liu C; Liu P; Lv J; Deng Z
    Ann Endocrinol (Paris); 2019 Apr; 80(2):77-83. PubMed ID: 30685058
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association of aberrant methylation of tumor suppressor genes with tumor aggressiveness and BRAF mutation in papillary thyroid cancer.
    Hu S; Liu D; Tufano RP; Carson KA; Rosenbaum E; Cohen Y; Holt EH; Kiseljak-Vassiliades K; Rhoden KJ; Tolaney S; Condouris S; Tallini G; Westra WH; Umbricht CB; Zeiger MA; Califano JA; Vasko V; Xing M
    Int J Cancer; 2006 Nov; 119(10):2322-9. PubMed ID: 16858683
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The expression profile of integrin receptors and osteopontin in thyroid malignancies varies depending on the tumor progression rate and presence of BRAF V600E mutation.
    Chernaya G; Mikhno N; Khabalova T; Svyatchenko S; Mostovich L; Shevchenko S; Gulyaeva L
    Surg Oncol; 2018 Dec; 27(4):702-708. PubMed ID: 30449496
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of Biomarkers Based on Differentially Expressed Genes in Papillary Thyroid Carcinoma.
    Han J; Chen M; Wang Y; Gong B; Zhuang T; Liang L; Qiao H
    Sci Rep; 2018 Jul; 8(1):9912. PubMed ID: 29967488
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A population-based study of the three major variants of papillary thyroid carcinoma.
    Xu J; Zhang Y; Liu J; Qiu S; Wang M
    J Int Med Res; 2021 Feb; 49(2):300060520984618. PubMed ID: 33535844
    [TBL] [Abstract][Full Text] [Related]  

  • 28. BRAF(V⁶⁰⁰E) mutation and its association with clinicopathological features of papillary thyroid microcarcinoma: A meta-analysis.
    Ma YJ; Deng XL; Li HQ
    J Huazhong Univ Sci Technolog Med Sci; 2015 Aug; 35(4):591-599. PubMed ID: 26223933
    [TBL] [Abstract][Full Text] [Related]  

  • 29. BRAF V600E mutation and p27 kip1 expression in papillary carcinomas of the thyroid Rodolico V; Cabibi D; Pizzolanti G; Richiusa P; Gebbia N; Martorana A; Russo A; Amato MC; Galluzzo A; Giordano C
    Cancer; 2007 Sep; 110(6):1218-26. PubMed ID: 17685465
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The prevalence and prognostic value of BRAF mutation in thyroid cancer.
    Kebebew E; Weng J; Bauer J; Ranvier G; Clark OH; Duh QY; Shibru D; Bastian B; Griffin A
    Ann Surg; 2007 Sep; 246(3):466-70; discussion 470-1. PubMed ID: 17717450
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of Long Noncoding RNAs Deregulated in Papillary Thyroid Cancer and Correlated with BRAF
    Goedert L; Plaça JR; Fuziwara CS; Machado MCR; Plaça DR; Almeida PP; Sanches TP; Santos JFD; Corveloni AC; Pereira IEG; de Castro MM; Kimura ET; Silva WA; Espreafico EM
    Sci Rep; 2017 May; 7(1):1662. PubMed ID: 28490781
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Uncommon BRAF mutations in the follicular variant of thyroid papillary carcinoma: New insights.
    Rossi ED; Martini M; Bizzarro T; Capodimonti S; Cenci T; Lombardi CP; Pontecorvi A; Fadda G; Larocca LM
    Cancer Cytopathol; 2015 Oct; 123(10):593-602. PubMed ID: 26230187
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunohistochemical detection of the BRAF V600E mutation in papillary thyroid carcinoma. Evaluation against real-time polymerase chain reaction.
    Paja Fano M; Ugalde Olano A; Fuertes Thomas E; Oleaga Alday A
    Endocrinol Diabetes Nutr; 2017 Feb; 64(2):75-81. PubMed ID: 28440781
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Associations of the BRAF(V600E) mutation with sonographic features and clinicopathologic characteristics in a large population with conventional papillary thyroid carcinoma.
    Park AY; Son EJ; Kim JA; Youk JH; Park YJ; Park CS; Chang HS
    PLoS One; 2014; 9(10):e110868. PubMed ID: 25337709
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Key genes and pathways predicted in papillary thyroid carcinoma based on bioinformatics analysis.
    Yu J; Mai W; Cui Y; Kong L
    J Endocrinol Invest; 2016 Nov; 39(11):1285-1293. PubMed ID: 27250077
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lack of correlation between BRAF V600E mutational status and the expression profile of a distinct set of miRNAs in papillary thyroid carcinoma.
    Sheu SY; Grabellus F; Schwertheim S; Handke S; Worm K; Schmid KW
    Horm Metab Res; 2009 Jun; 41(6):482-7. PubMed ID: 19370505
    [TBL] [Abstract][Full Text] [Related]  

  • 37. BRAF mutation detection in indeterminate thyroid cytology specimens: underlying cytologic, molecular, and pathologic characteristics of papillary thyroid carcinoma.
    Ohori NP; Singhal R; Nikiforova MN; Yip L; Schoedel KE; Coyne C; McCoy KL; LeBeau SO; Hodak SP; Carty SE; Nikiforov YE
    Cancer Cytopathol; 2013 Apr; 121(4):197-205. PubMed ID: 22887810
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tall cell variant of papillary thyroid microcarcinoma: clinicopathologic features with BRAF(V600E) mutational analysis.
    Bernstein J; Virk RK; Hui P; Prasad A; Westra WH; Tallini G; Adeniran AJ; Udelsman R; Sasaki CT; Roman SA; Sosa JA; Prasad ML
    Thyroid; 2013 Dec; 23(12):1525-31. PubMed ID: 23682579
    [TBL] [Abstract][Full Text] [Related]  

  • 39. BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma.
    Costa AM; Herrero A; Fresno MF; Heymann J; Alvarez JA; Cameselle-Teijeiro J; García-Rostán G
    Clin Endocrinol (Oxf); 2008 Apr; 68(4):618-34. PubMed ID: 18070147
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical Manifestations and Gene Expression in Patients with Conventional Papillary Thyroid Carcinoma Carrying the BRAF(V600E) Mutation and BRAF Pseudogene.
    Lin JD; Fu SS; Chen JY; Lee CH; Chau WK; Cheng CW; Wang YH; Lin YF; Fang WF; Tang KT
    Thyroid; 2016 May; 26(5):691-704. PubMed ID: 26914762
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.